Canada's Alberta confirms first death linked to AstraZeneca vaccine

Alberta case marks the second case of blood clots, and the only death after more than 253,000 doses

  
A medic shows a vial of AstraZeneca's COVISHIELD coronavirus disease (COVID-19) vaccine in Yangon, Myanmar, after the country received 1.5 million doses of the vaccine manufactured by the Serum Institute of India, January 27, 2021.

A medic shows a vial of AstraZeneca's COVISHIELD coronavirus disease (COVID-19) vaccine in Yangon, Myanmar, after the country received 1.5 million doses of the vaccine manufactured by the Serum Institute of India, January 27, 2021.

REUTERS/Shwe Paw Mya Tin

The Canadian province of Alberta reported its first death of a patient from a rare blood clot condition after receiving the AstraZeneca COVID-19 vaccine, its chief medical officer confirmed late Tuesday.

The Alberta case marks the second case of blood clots, and the only death after more than 253,000 doses of AstraZeneca were administered in the province, the statement added.

AstraZeneca did not immediately respond to Reuters' request for a comment.

Last month, the province of Quebec reported Canada's first death of a patient after receiving the AstraZeneca COVID-19 vaccine. 

The rare complication, which some regulators including Health Canada are calling Vaccine-Induced Prothrombotic Immune Thrombocytopenia, involves blood clots accompanied by a low count of platelets, cells in the blood that help it to clot.

(Reporting by Sabahatjahan Contractor in Bengaluru, Editing by Sherry Jacob-Phillips) ((Sabahatjahan.Contractor@thomsonreuters.com; within U.S. +1 646 223 8780 outside the U.S. +918067492635;))

More From Health